EMA Authorised: Adzynma (rADAMTS13) — Takeda Manufacturing Austria AG

View source ↗

Summary

The European Medicines Agency authorized Adzynma (rADAMTS13) for the treatment of thrombotic thrombocytopenic purpura and granted orphan medicine status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• Adzynma

Snippet

Status: Authorised. Therapeutic area: Purpura, Thrombotic Thrombocytopenic. MAH: Takeda Manufacturing Austria AG. Decision date: 09/01/2026. Orphan medicine